News & Stories
See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.
Roadblocks on the Road to Curing Charcot-Marie-Tooth (CMT)
It seems like every other day we hear about a new drug that has been approved for a rare neurologic disease. Increased understanding of the genetics underlying these diseases has led to numerous new gene therapies. Why have we not yet seen similar successes in CMT? In...
CMT1A Research Update
CMT1A is caused by a duplication of the PMP22 gene leading to overexpression of the PMP22 protein and failure of the Schwann cells to produce myelin (the insulation of the nerve) well. Without proper myelination, the nerves don’t send signals quickly or strongly,...
CMTRF Welcomes Dr. Grace Pavlath as Chief Science Officer
CMT Research Foundation (CMTRF), a not-for-profit organization focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, has added Grace Pavlath, Ph.D. to the team as the new Chief Scientific Officer. CMT is a progressive genetic nerve disease...
Scenes from BIO2019
Last week Paul August and I attended the BIO International Convention, a conference with over 16,000 leaders from the biotech and pharmaceutical industry. We met a number of companies interested in advancing drug development for CMT. There are four primary factors...
Partnerships and Priorities: The Pathway to CMT Results
From time to time the CMT Research Foundation will examine the impediments to finding a cure for CMT. As the Chairman of a nonprofit foundation whose ONLY mission is to fund research that will lead to a cure for Charcot-Marie-Tooth disease (CMT), I am often...
The Inherited Neuropathy Consortium (INC) welcomes the CMT Research Foundation as a partner in their Patient Advocacy Groups
Today the Inherited Neuropathy Consortium (INC) named the CMT Research Foundation as a partner in their Patient Advocacy Groups. This gives the CMT Research Foundation access to INC resources, researchers and its clinical infrastructure through 21 CMT Centers of...
Is there a connection between CMT1X and Multiple Sclerosis?
A recent study by Georgios Koutis et al at the National and Kapodistrian University of Athens recently published a paper in The Journal of Neurology, Neurosurgery and Psychiatry suggesting emerging evidence of a connection between CMTX1 and Multiple Sclerosis (MS)....
CMT Research Foundation Adds Dr. Charles Abrams and Jeff Ellman To The Team
CMT Research Foundation (CMTRF), focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, added Jeff Ellman to its Board of Directors and Charles Abrams MD, Ph.D, to its Scientific Advisory Board. CMT is a progressive genetic nerve disease...
Where We Started, How Far We Have Come and Where We are Going
The CMT Research Foundation offers hope to those living with CMT that a treatment and cure are on their way!
$1,000,000 pledge to CMT research
CMTRF Receives $1 Million Research Grant from Grandview Steers Foundation The pace of research for CMT just got faster. Atlanta (November 8, 2018) The newly launched CMT Research Foundation (CMTRF), the only 501(c)(3) not-for-profit organization focused solely on...
Address
4062 Peachtree Road
Suite A209
Atlanta, GA 30319
Phone Number
404.806.7180
Media Inquiries
© 2024 CMT Research Foundation | Privacy Policy